Quantcast

Latest Aripiprazole Stories

2010-11-16 10:39:00

BURLINGTON, Mass., Nov. 16, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that first-line use of Bristol Myers-Squibb/Otsuka's Abilify has increased over the past year in newly-diagnosed patients from 4.1 percent patient share to 8.8 percent. According to Treatment Algorithms in Bipolar Disorder, uptake of Abilify in the first-line will continue among surveyed primary care physicians (PCPs):...

2010-04-12 07:00:00

WALTHAM, Mass., April 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed psychiatrists say that the decrease in severity of manic symptoms is the attribute that most influences their prescribing decisions in bipolar mania. Clinical data and the opinions of interviewed thought leaders indicate that Eli Lilly's Zyprexa (olanzapine) has advantages in this attribute over...

2010-02-23 08:00:00

WALTHAM, Mass., Feb. 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the world's major pharmaceutical markets, emerging oral atypical antipsychotics will compete against each other and against established drugs for the same niche patient population in the treatment of schizophrenia. The Pharmacor 2010 findings from the topic entitled Schizophrenia reveals that emerging oral atypical...

2010-01-04 16:21:16

Despite government warnings and professional recommendations about diabetes risks associated with second-generation antipsychotic drugs, fewer than one-third of Medicaid patients who are treated with these medications undergo tests of blood glucose or lipid levels, according to a report in the January issue of Archives of General Psychiatry, one of the JAMA/Archives journals. In 2003, the Food and Drug Administration (FDA) began requiring a warning on labels of second-generation...

2009-12-02 07:00:00

WALTHAM, Mass., Dec. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that generic erosion of several established branded atypical antipsychotics will cause the schizophrenia drug market to decrease from $6.3 billion in 2008 to $5.2 billion in 2013 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The new Pharmacor report entitled Schizophrenia finds that the...

2009-11-05 07:00:00

WALTHAM, Mass., Nov. 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that widespread generic erosion of branded atypical antipsychotics will cause the bipolar disorder drug market to decline from $6.3 billion in 2008 to approximately $5 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The new Pharmacor report entitled Bipolar Disorder finds that the...

69ebba93937a01a1551131e73148d2ae1
2009-10-29 12:41:05

A new study has shown that antipsychotic drugs may be linked to weight gain in kids. Writing in the Journal of the American Medical Association (JAMA), researchers studied the use of name-brand second-generation anti-psychotic drugs, including Abilify, Risperdal, Seroquel and Zyprexa, in 272 kids aged 4 to 19 years. Children involved in the study had not been previously treated with anti-psychotic drugs. "First-time second-generation antipsychotic medication use was associated with...

2009-10-27 16:25:53

Many pediatric and adolescent patients who received second-generation antipsychotic medications experienced significant weight gain, along with varied adverse effects on cholesterol and triglyceride levels and other metabolic measures, according to a study in the October 28 issue of JAMA. Treatment for psychotic disorders, bipolar disorder, and nonpsychotic mental disorders for children and adolescents in the United States often includes second-generation antipsychotic medications....

2009-07-23 07:00:00

WALTHAM, Mass., July 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the patient share of Bristol-Myers Squibb/Otsuka's Abilify has grown in the first three lines of therapy since the 2008 analysis of prescribing trends in newly diagnosed schizophrenia patients. Abilify is second to risperidone (Janssen's Risperdal, generics) in first and second lines of therapy and leads other...

2009-06-22 10:00:00

Although Risperidone Is Now Available In Generics, There Is No Clear Evidence of Expanded Uptake in Early Lines of Therapy, According to a New Report from Decision Resources Patient-Flow Forecasts Need to Take Into Account Shifts in Seroquel XR's Use by Line of Therapy Over the Next Two Years WALTHAM, Mass., June 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that AstraZeneca Seroquel's...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related